Epithelioid hemangio-endothelioma (EHE) in NETSARC: The nationwide series of 267 patients over 12 years.

[1]  D. Carpizo,et al.  A review of hepatic epithelioid hemangioendothelioma—Analyzing patient characteristics and treatment strategies , 2022, Journal of surgical oncology.

[2]  Robin L. Jones,et al.  Retrospective observational studies in ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society (CTOS) community of experts on the minimum requirements for the evaluation of activity of systemic treatments. , 2022, Cancer treatment reviews.

[3]  J. Sicklick,et al.  Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. , 2022, Journal of the National Comprehensive Cancer Network : JNCCN.

[4]  R. Maki,et al.  SELNET Clinical practice guidelines for bone sarcoma. , 2022, Critical reviews in oncology/hematology.

[5]  A. Gronchi,et al.  Treatment modalities and long-term outcomes of hepatic hemangioendothelioma in the United States. , 2022, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[6]  F. Bertucci,et al.  Patterns of care and outcomes of 417 patients with METAstatic SYNovial sarcoma (METASYN): real-life data from the French Sarcoma Group (FSG) , 2022, ESMO open.

[7]  C. M.,et al.  SELNET clinical practice guidelines for soft tissue sarcoma and GIST. , 2021, Cancer treatment reviews.

[8]  S. Sleijfer,et al.  Bone sarcomas: ESMO-EURACAN-GENTURIS-ERNPaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  A. B. Hassan,et al.  Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  W. T. van der Graaf,et al.  The heterogeneity of Epithelioid Hemangioendothelioma (EHE): A case series and review of the literature with emphasis on treatment options. , 2021, Seminars in oncology.

[11]  C. Antonescu,et al.  Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts , 2021, ESMO open.

[12]  David M. Thomas,et al.  Ultra‐rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities , 2021, Cancer.

[13]  S. Gitelis,et al.  Epithelioid hemangioendothelioma of bone: A survival analysis of 50 cases from the SEER database (1992–2016) , 2021, Rare tumors.

[14]  Robin L. Jones,et al.  Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature , 2021, Cancer medicine.

[15]  A. Caraceni,et al.  Clinical prognostic factors in advanced epithelioid haemangioendothelioma: a retrospective case series analysis within the Italian Rare Cancers Network , 2021, ESMO open.

[16]  L. Mariani,et al.  Activity of sirolimus in patients with progressive epithelioid hemangioendothelioma: A case‐series analysis within the Italian Rare Cancer Network , 2020, Cancer.

[17]  J. Blay,et al.  Pregnancy in Women with Metastatic Sarcomas , 2020, The Oncologist.

[18]  J. Blay,et al.  Nationwide incidence of sarcomas and connective tissue tumors of intermediate malignancy over four years using an expert pathology review network , 2020, medRxiv.

[19]  Robin L. Jones,et al.  The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients. , 2020, European journal of cancer.

[20]  Robin L. Jones,et al.  The Role of Local Therapy in Multi-focal Epithelioid Haemangioendothelioma , 2019, AntiCancer Research.

[21]  J. Blay,et al.  Surgery in reference centers improves survival of sarcoma patients: a nationwide study , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  J. Blay,et al.  Very long‐term survivors among patients with metastatic soft tissue sarcoma , 2019, Cancer medicine.

[23]  M. Agulnik,et al.  Epithelioid Hemangioendothelioma: Update on Diagnosis and Treatment , 2018, Current Treatment Options in Oncology.

[24]  J. Blay,et al.  Presentation and outcome of frequent and rare sarcoma histologic subtypes: A study of 10,262 patients with localized visceral/soft tissue sarcoma managed in reference centers , 2018, Cancer.

[25]  F. Bertucci,et al.  Improved survival using specialized multidisciplinary board in sarcoma patients , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  Robin L. Jones,et al.  Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis , 2017, Acta oncologica.

[27]  M. Wachtel,et al.  Treatment of Hepatic Epithelioid Hemangioendothelioma: Finding Uses for Thalidomide in a New Era of Medicine , 2015, Case reports in gastrointestinal medicine.

[28]  J. Blay,et al.  Eight years tumor control with pazopanib for a metastatic resistant epithelioid hemangioendothelioma , 2015, Clinical Sarcoma Research.

[29]  J. Gugenheim,et al.  Metastatic Hepatic Epithelioid Hemangio-Endothelioma: Long-Term Response to Sunitinib Malate , 2014, Oncology Research and Treatment.

[30]  M. Rubin,et al.  Novel YAP1‐TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma , 2013, Genes, chromosomes & cancer.

[31]  J. Blay,et al.  Sorafenib in patients with progressive epithelioid hemangioendothelioma , 2013, Cancer.

[32]  Joannie T. Yeh,et al.  Clinical patterns and outcome in epithelioid hemangioendothelioma with or without pulmonary involvement: insights from an internet registry in the study of a rare cancer. , 2011, Chest.

[33]  C. Antonescu,et al.  A novel WWTR1‐CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites , 2011, Genes, chromosomes & cancer.

[34]  C. Fletcher,et al.  Epithelioid hemangioendothelioma of skin and soft tissues: clinicopathologic and immunohistochemical study of 30 cases. , 1997, The American journal of surgical pathology.

[35]  S. Broski,et al.  Epithelioid hemangioendothelioma: evaluation by 18F-FDG PET/CT. , 2021, American journal of nuclear medicine and molecular imaging.

[36]  A. Crombé,et al.  [Epithelioid hemangioendothelioma]. , 2019, Bulletin du cancer.

[37]  C. Fisher,et al.  Systemic treatment options for epithelioid haemangioendothelioma: the Royal Marsden Hospital experience. , 2015, Anticancer research.

[38]  M. von Mehren,et al.  An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[39]  O. S. Nielsen,et al.  Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy. , 2003, European journal of cancer.